INTRODUCTION
Subtle clinical presentations of Cushing's syndrome, characterized by a paucity of signs and symptoms due to mild cortisol hypersecretion, are increasingly found in clinical practice. In parallel, the metabolic syndrome epidemic is leading to a boost in the number of patients with a Cushingoid phenotype, who could be potentially candidate to be tested for hypercortisolism (1).
The Endocrine Society guidelines for the diagnosis of Cushing's syndrome recommended against widespread testing for the condition, unless in patients with unusual features for age, or multiple and progressive features, particularly those that are more predictive of Cushing's syndrome (2) .
However, unsuspected Cushing's syndrome was found to be more frequent than previously expected in different series of diabetic patients submitted to routine screening (3, 4, 5) . Thus, a number of patients with Cushing's syndrome may not be recognized while they are managed for diabetes, either because of a mild clinical presentation or because of insufficient awareness of their physicians. Missing a diagnosis of Cushing's syndrome may have detrimental consequences on patient outcome because hypercortisolism is expected to worsen metabolic control and increase the probability of future cardiovascular events (6) .
The results of the above-mentioned studies may argue in favor of a systematic screening of Cushing's syndrome in type 2 diabetes. However, data were mostly generated in academic centers on hospitalized patients, thus raising the possibility of a selection bias toward patients at greater risk of Cushing's syndrome than the general diabetic population (7) .
The aim of our study was to screen patients attending diabetes clinics in an outpatient setting and in conditions of standard clinical practice. Cohorts of consecutive patients were enrolled in different Italian diabetes clinics rather than selecting groups of patients at higher risk for Cushing's, i.e. those who were hypertensive, overweight, and had poor glycemic control.
PATIENTS and METHODS

Patients
The study was conducted under the auspices of the Associazione Medici Endocrinologi (AME) at 24 diabetes clinics across Italy (Fig/table 1) . Written informed consent was obtained from all patients, and the institutional review board at each center approved the study. Each participating center was requested to recruit consecutively at least 20 diabetic patients fulfilling all inclusion criteria and without exclusion criteria, who were attending the center for an ordinary outpatient visit from June 2006 to April 2008. Followup for this study was closed in September 2010. Patients had to meet the following inclusion criteria: age between 18 and 70 years, BMI greater than 25 kg/m 2 and known diagnosis of type 2 diabetes on active follow-up from at least 1 year before the study. Exclusion criteria were presence of specific Cushingoid features (easy bruising, facial plethora, proximal miopathy and striae (2)), any severe acute illness, treatment with drugs known to affect the HPA axis or dexamethasone metabolism, current or previous history of alcohol abuse or major mood disorders that required psychiatric intervention, history of recent surgery or trauma and pregnancy. Any subject with BMI greater than 30 kg/m 2 was categorized as obese (8). Any subject with systolic blood pressure greater than 140 mmHg, diastolic blood pressure greater than 90 mmHg, or on antihypertensive treatment was categorized as hypertensive (9). Dyslipidemia was defined following the ATP-III criteria: total cholesterol >200 mg/dl, high-density lipoprotein cholesterol levels <40 mg/dl, serum triglyceride levels >150 mg/dl, low-density lipoprotein cholesterol levels >160 mg/dl (10). Patients were also considered dyslipidemic if any specific treatment was given. The main characteristics of the evaluated patients are shown in Table 1 .
Materials and protocols
All subjects underwent in an outpatient setting a first screening step by using the overnight 1-mg dexamethasone suppression test (DST) (1 mg dexamethasone administered orally at 2300 h, and blood sample drawing on the following morning at 0800 h for determination of serum cortisol concentration. Patients who failed to suppress serum cortisol less than 5.0 g/dl (138 nmol/l) were offered a second-step evaluation by undergoing a standard 2-day 2-mg DST, 3-6 months after baseline evaluation (0.5 mg dexamethasone administered orally at 06.00, 12.00, 18.00 and 24.00 h, and blood sample drawing on the following morning at 0800 h for cortisol determination). A cortisol concentration greater than 1.8 g/dl (50 nmol/l) was considered abnormal and prompted further evaluation to confirm diagnosis of Cushing's syndrome and determine its cause according to a standardized protocol (11). The study flow-chart is outlined in Figure 1 . 
DISCUSSION
Previous studies have shown a prevalence of unsuspected Cushing's syndrome in patients with type 2 diabetes ranging from 0% to 9.4%, even if surgical prove was secured in a minority of cases only ( (Table 4 ).
In the present study, we observed a frequency of previously unsuspected The frequency of occult Cushing's syndrome reported herein was lower than in previous studies employing a similar screening strategy (3, 4, 5) and this is likely explained by two factors. First, in our study screening was done in an unselected population and not only in patients at perceived high risk of hypercortisolism. It is pertinent to consider that different procedures of screening proved to be ineffective in an outpatient setting, although the studies had less statistical power than the present one (16, 17, 18, 19) .
Second, the use of a more specific cutoff point for the 1-mg DST at 5.0 g/dl (138 nmol/l). This was deemed appropriate since the study was done in conditions of standard clinical practice and not in academic, referral centers.
Our choice was aimed at limiting additional workload and costs of screening to select patients with more than minimal hypercortisolism, likely associated with clinical consequences. The entity of hypercortisolism was indeed slight in one case only, with a presumably pituitary adenoma.
In previous studies, the use of cutoff points ranging from 1.8 g/dl (50 nmol/l) to 2.1 g/dl (58 nmol/l) was associated with a high false-positive rate due to the poor specificity of these thresholds (3, 4, 20) , whereas a cutoff point at 4.0 g/dl (110 nmol/l) provided comparable results (21) . Would have we used the most sensitive cutoff of 1.8 g/dl (50 nmol/l), as many as 22.6% of patients should have been submitted to further testing. This observation demonstrates clearly that a screening strategy aimed at maximal sensitivity, that should be advocated in principle, is virtually impossible to apply in the every-day practice. However, we cannot exclude to have missed a number of patients with subclinical Cushing's syndrome, that is associated with subtler alterations of the HPA axis (22) . This observation does not limit the clinical relevance of our results, since it remains controversial whether subclinical Cushing's syndrome is associated with long-term morbidity and whether treatment to reverse this disorder may be beneficial (7, 22, 23) .
Two issues are key to the justification of large-scale screening of Cushing's syndrome. First, is occult Cushing's syndrome associated with a more severe metabolic and cardiovascular disease and, second, does its cure have a beneficial impact on the outcome of patients? These issues remain mostly undefined by the available studies, because of the small number of patients who were found to have Cushing and were submitted to specific treatment (Table 4 ). In addition, none of the previous studies reported on long-term data after successful treatment of occult Cushing's syndrome. Discrepant results were reported concerning severity of diabetes in occult Cushing (3, 4) ; however, amelioration of diabetes has been reported in the few patients who attained remission of hypercortisolism (3, 4, 21) .
In the present study, we observed that the condition of being nonsuppressor to dexamethasone was associated with higher glycemic levels, notwithstanding that a greater proportion of such patients were on insulin treatment. However, this association seems to reflect a secondary activation of the HPA axis in patients with more severe metabolic derangement (24, 25), since we observed a positive relationship between HbA1c values and post-dexamethasone cortisol levels.
We were able to attain long-term follow-up data of the patients with definitive Cushing's syndrome, thus confirming that surgical cure was associated with significant improvement of metabolic control in the 4 patients who underwent removal of their adrenal adenoma ( Table 3) . Diagnosis of Cushing's syndrome was useless in a patient in poor general conditions, who is still untreated. Due to the small numbers, we cannot definitively prove that screening of Cushing's syndrome results in a more favorable outcome of the patients who were diagnosed with the condition. However, it is noteworthy that all the treated patients were able to discontinue, or reduce, medications for diabetes after remission of hypercortisolism.
In conclusion, the results of the present study do not support the application of a wide-scale screening of Cushing's syndrome in patients with type 2 diabetes, unless more efficient screening procedures will become available. The frequency of Cushing's syndrome in an unselected patient population was low compared to the number of false positive results to make a routine screening strategy applicable in practice.
Considering the epidemic of type 2 diabetes in the Western World, however, the present data suggest that Cushing's syndrome is less rare than previously found (although not frequent enough to warrant systematic screening Abbreviations are as follows: T2DM, type 2 diabetes; HTN, hypertension; DST, dexamethasone suppression test; OHA, oral hypoglycemic agents; I, insulin; CT, computerized tomography; ADX, adrenalectomy; BMAH, bilateral macronodular adrenal hyperplasia; MRI, magnetic resonance imaging.
Figure1
Algorithm of the screening strategy used in 813 patients with type-2 diabetes. 
